University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Big Data Shows How Cancer Interacts with Its Surroundings

Big Data Shows How Cancer Interacts with Its Surroundings

October 20, 2017

By combining data from sources that at first seemed to be incompatible, UC San Francisco researchers have identified a molecular signature in tissue adjacent to tumors in eight of the most common cancers that suggests they are all using the same mechanism to remodel normal ...
Researchers to Combat Drug-Resistant Lung Cancer at New NCI-Funded Center at UCSF

Researchers to Combat Drug-Resistant Lung Cancer at New NCI-Funded Center at UCSF

October 19, 2017

The National Cancer Institute (NCI) has announced that UC San Francisco will host one of five new Cancer Drug Resistance and Sensitivity Centers being set up around the U.S. through funding from the 21st Century Cures Act of 2016.    The center, a collaboration with ...
Renowned Cancer Virologists to Deliver Annual Sokolow Lectureship

Renowned Cancer Virologists to Deliver Annual Sokolow Lectureship

October 12, 2017

Two of the sharpest minds in the field of cancer virology are scheduled to present the Maurice, Ethel, and Jane Sokolow Memorial Cancer Endowment Lectureship at the HDFCCC on October 25th and 26th. Yuan Chang, MD, and Patrick S. Moore, MD, MPH, from the University ...
Hard-Core Smokers are Softening Over Time

Hard-Core Smokers are Softening Over Time

October 10, 2017

Cigarette smokers with high levels of psychological distress are often heavy smokers, and thus identified as a “hard core” group who are less willing or able to quit than other smokers. However, a study by UC San Francisco researchers shows that over the course of ...
UCSF First in State to Provide FDA-Approved CAR-T for Pediatric Cancer Patients

UCSF First in State to Provide FDA-Approved CAR-T for Pediatric Cancer Patients

September 18, 2017

UCSF Benioff Children’s Hospital San Francisco has been certified as the first medical center in California to provide CAR-T therapy for children and young adults with acute lymphoblastic leukemia (ALL), who have failed standard treatment.